Results 261 to 270 of about 176,622 (333)

NCOG-25. Comparison of Dosing Strategies of Bevacizumab for Radiation Necrosis: A Retrospective Study [PDF]

Milisia Labib, Sydney Schultz, Kristin Cole, Scott Soefje, Jodi Taraba, Gena Hoefs, Joon Uhm, Sani Kizilbash, Michael R. Ruff, Ugur Sener   +9 more
openalex   +1 more source

Response to Letter to the Editor re: a phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study): KRAS mutations in colorectal cancer patients receiving trifluridine/tipiracil plus bevacizumab: something to consider. [PDF]

ESMO Open
Wakabayashi M, Taniguchi H.
europepmc   +1 more source

Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

International Journal of Cancer, Volume 157, Issue 12, Page 2577-2588, 15 December 2025.
What's New? Platinum‐based chemotherapy is the first‐line treatment for unresectable gastrointestinal neuroendocrine carcinoma (NEC). Which treatments are most effective following platinum‐based regimens remains unclear. In this study, the authors compared clinical outcomes between NEC patients who received second‐ or later‐line treatments either with ...
Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, Hidekazu Hirano, Saori Mishima, Hiroyuki Takahashi, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Kentaro Kawakami, Katsunori Shinozaki, Kenji Tsuchihashi, Takayuki Ando, Yosuke Kito, Akitaka Makiyama, Seiichiro Mitani, Kaori Hino, Naoki Izawa, Isao Oze, Kei Muro   +29 more
wiley   +1 more source

Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

PLoS One
Xiang H, She Z, Wang L, Peng Y, Zhang L, Tan C.   +5 more
europepmc   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, Volume 19, Issue 12, Page 3750-3768, December 2025.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Case report of curative resection after preoperative bevacizumab and sintilimab therapy in hepatocellular carcinoma with lymph node metastasis. [PDF]

Discov Oncol
Pang S, Yang Y, Sun Z, Yang N.
europepmc   +1 more source

Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)

Cancer Innovation, Volume 4, Issue 6, December 2025.
“The core objective of this guideline is to personalize the management of advanced breast cancer through molecular subtyping, optimizing the balance between survival and quality of life. We integrate recent evidence‐based advances and underscore the essential roles of multidisciplinary collaboration and management of patient‐reported outcomes (PROs ...
Breast Cancer Expert Committee of the National Quality Control Center for Cancer, Breast Cancer Expert Committee of the China Anti‐Cancer Association, Cancer Drug Clinical Research Committee of the China Anti‐Cancer Association   +2 more
wiley   +1 more source

Gastropleural Fistula Following Combined TACE, Immunotherapy, and Bevacizumab in HCC: A Case Report. [PDF]

J Hepatocell Carcinoma
Xu X, Li J, Pan L, Yu H, Huang J.
europepmc   +1 more source

Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens

Cancer Innovation, Volume 4, Issue 6, December 2025.
Metronomic chemotherapy (MCT) in breast cancer enhances antitumor efficacy through continuous low‐dose drug administration, reducing toxicity and improving quality of life. Combined with immunotherapy, endocrine therapy, or targeted agents, MCT reshapes the tumor microenvironment, delays resistance, and prolongs survival.
Jiaxuan Liu, Hongnan Mo, Qiao Li, Marina Elena Cazzaniga, Fei Ma   +4 more
wiley   +1 more source

Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis. [PDF]

Cost Eff Resour Alloc
Zhang Y, Zhou T, Wu N, Bai Z, Wei J, Cai N, Xu S.   +6 more
europepmc   +1 more source